7Baggers
 Published on: 2025-11-14 13:13:47  Fundação Cultural do Pará Fri, 14 Nov 2025 16:16:05 GMT
 cel-sci extends shareholder rights agreement to 2030  MSN Fri, 07 Nov 2025 05:11:13 GMT
 published on: 2025-11-06 07:36:10  Fundação Cultural do Pará Thu, 06 Nov 2025 10:36:10 GMT
 Cel-Sci Extends Shareholder Rights Agreement to 2030  TipRanks Wed, 05 Nov 2025 08:00:00 GMT
 CEL-SCI Shares: Navigating Biotech’s Rollercoaster Ride  AD HOC NEWS Wed, 05 Nov 2025 08:00:00 GMT
 tangible book value per share of cel-sci corporation – mun:lsr  TradingView Mon, 03 Nov 2025 13:58:08 GMT
 published on: 2025-11-03 02:04:39  newser.com Mon, 03 Nov 2025 08:04:39 GMT
 published on: 2025-11-02 22:20:43  newser.com Mon, 03 Nov 2025 03:20:43 GMT

CEL-SCI Corporation
(NYSE MKT:CVM) 

CVM stock logo

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antig...

Founded: 1983
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends